Video

Bispecifics in Multiple Myeloma: Dosing and Transition of Care

Author(s):

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

Related Videos
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Daniel DeAngelo, MD, PhD
Related Content
David R. Oveisi, MD
November 20th 2024

Expanded Indications for CAR T-Cell Therapies Shepard in New Era of Myeloma Care

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

LASZLO – stock.adobe.com
November 14th 2024

Belantamab Mafodotin Plus Bortezomib/Dexamethasone Extends OS in R/R Myeloma

PD-L1, KIM-1 Expression in ccRCC | Image Credit: © Cornflakesei - stock.adobe.com
November 8th 2024

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC